Skip to main content

Table 3 Comparison of patient characteristics by first-line therapies

From: Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade

 

Abi (n = 26)

Enz (n = 43)

Doce (n = 25)

p-value

Mean (SD) age at CRPC diagnosis (years)

78.8 (8.8)*

77.8 (8.3)*

69.0 (7.5)

< 0.001

Initial PSA

1313.2 (2561.2)

533.1 (1653.2)

713.3 (1033.5)

0.242

TNM classification at the diagnosis of prostate cancer

    

 T1

0

3

1

0.65

 T2

4

8

5

 

 T3

11

21

13

 

 T4

11

11

6

 

 N1 or higher

13

23

14

0.91

 M1

20

30

17

0.74

Gleason scores

   

0.63

 6

0

2

0

 

 7

1

1

2

 

 8

2

9

4

 

 9

20

24

16

 

 10

2

5

3

 

 Unknown

1

2

0

 
  1. Abi abiraterone, CRPC castration-resistant prostate cancer; Doce docetaxel, Enz enzalutamide, PSA prostate-specific antigen; SD standard deviation
  2. *p < 0.05, vs. Group Doce by Turkey-Kramer test